Aura Biosciences, Inc.
Description
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
About
CEO
Dr. Elisabet de los Pinos Ph.D.
Employees
88
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
80 Guest Street, Boston, MA 02135, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 13, 2024 | -0.44 | -0.42 | 0.02 | -4.55% |
| Aug 8, 2024 | -0.45 | -0.41 | 0.04 | -8.89% |
| May 9, 2024 | -0.49 | -0.40 | 0.09 | -18.37% |
| Mar 27, 2024 | -0.41 | -0.56 | -0.15 | 36.59% |
| Nov 10, 2023 | -0.52 | -0.48 | 0.04 | -7.69% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 0 |
| Average estimate | — | 0.00 | — | 0.00 |
| Low estimate | — | 0.00 | — | 0.00 |
| High estimate | — | 0.00 | — | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 65.23M | 42.24M | 25.16M | 18.04M | 19.62M |
| Selling general and admin | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -84.99M | -60.30M | -35.25M | -22.21M | -24.14M |
| Non operating interest income | |||||
| Income | 8.59M | 1.86M | 13,000 | — | — |
| Expense | — | — | — | 3,000 | 5,000 |
| Other income expense | 132,000 | -332,000 | -14,000 | 3,000 | -55,000 |
| Pretax income | -76.27M | -58.76M | -35.25M | -22.21M | -24.20M |
| Tax provision | 137,000 | — | — | — | — |
| Net income | -76.41M | -58.76M | -35.25M | -22.21M | -24.20M |
| Basic EPS | -1.93 | -1.96 | -8.95 | -1.54 | -1.74 |
| Diluted EPS | -1.93 | -1.96 | -8.95 | -1.54 | -1.74 |
| Basic average shares | 39.62M | 29.94M | 5.16M | 19.57M | 13.89M |
| Diluted average shares | 39.62M | 29.94M | 5.16M | 19.57M | 13.89M |
| EBITDA | -83.90M | -58.80M | -34.42M | -21.38M | -23.63M |
| Net income from continuing op. | -76.41M | -58.76M | -35.25M | -22.21M | -24.20M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 255.08M | 223.94M | 160.03M | 22.10M | 37.06M |
| Current assets | |||||
| Cash | — | — | — | 17.39M | 32.45M |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 41.06M | 121.58M | 149.06M | 17.39M | 32.45M |
| Other short term investments | 185.09M | 67.23M | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 3.22M | 7.16M | 4.55M | 1.03M | 822,000 |
| Restricted cash | 19,000 | 20,000 | 23,000 | 19,000 | 19,000 |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 2.41M | 715,000 | 66,000 | 16,000 | 56,000 |
| Non current assets | |||||
| Properties | 26.65M | 28.10M | 6.52M | 4.71M | 3.89M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 289,000 | 133,000 | 63,000 | 64,000 | 64,000 |
| Construction in progress | 391,000 | 1.81M | 2.37M | 1.15M | 1.20M |
| Leases | — | — | 13,000 | — | — |
| Accumulated depreciation | -5.04M | -3.86M | -2.76M | -2.35M | -1.52M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 1.28M | 1.19M | 125,000 | 75,000 | 75,000 |
| Total liabilities | 29.23M | 28.35M | 7.72M | 2.74M | 124.46M |
| Current liabilities | |||||
| Accounts payable | 1.79M | 2.92M | 2.40M | 611,000 | 2.33M |
| Accrued expenses | 3.45M | 1.54M | 1.69M | 750,000 | 2.11M |
| Short term debt | 2.69M | 2.96M | 615,000 | 15,000 | — |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 3.50M | 2.71M | 2.15M | 1.02M | 1.30M |
| Other current liabilities | 935,000 | 325,000 | 506,000 | 277,000 | 405,000 |
| Non current liabilities | |||||
| Long term debt | 16.87M | 17.90M | 360,000 | — | 49,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | 83,000 | 72,000 | 75,000 |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | — | — | — | — | — |
| Retained earnings | -287.31M | -210.90M | -152.14M | -116.89M | -94.68M |
| Other shareholders equity | 539,000 | -72,000 | — | — | — |
| Total shareholders equity | 225.85M | 195.58M | 152.32M | 19.36M | -87.41M |
| Additional paid in capital | 512.62M | 406.56M | 304.45M | 8.17M | 7.27M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -76.41M | -58.76M | -35.25M | -22.21M | -24.20M |
| Depreciation | 1.30M | 1.18M | 831,000 | 831,000 | 509,000 |
| Deferred Taxes | — | — | — | — | — |
| Stock-Based Compensation | 8.77M | 6.41M | 2.31M | 736,000 | 507,000 |
| Other Non-Cash Items | 1.84M | 968,000 | 15,000 | -3,000 | 43,000 |
| Accounts Receivable | — | — | — | — | — |
| Accounts Payable | -1.04M | 340,000 | 1.05M | -1.72M | 1.04M |
| Other Assets & Liabilities | -1.41M | -1.17M | — | — | — |
| Operating Cash Flow | -66.95M | -51.03M | -31.04M | -22.36M | -22.10M |
| Investing Activities | |||||
| Capital Expenditures | -709,000 | -1.09M | -2.13M | -771,000 | -2.22M |
| Net Intangibles | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — |
| Purchase of Investments | -233.65M | -119.78M | — | — | — |
| Sale of Investments | 120.40M | 53.01M | — | — | — |
| Investing Cash Flow | -113.96M | -67.87M | -2.13M | -771,000 | -2.22M |
| Financing Activities | |||||
| Long-Term Debt Issuance | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | -34,000 | -37,000 |
| Other Financing Charges | — | — | -15,000 | -34,000 | — |
| Financing Cash Flow | 95.79M | 95.20M | 165.91M | 9.84M | 39.67M |
| Other Cash Details | |||||
| End Cash Position | 41.85M | 122.37M | 149.21M | 17.49M | 32.54M |
| Income Tax Paid | — | — | — | — | — |
| Interest Paid | — | — | — | — | — |
| Free Cash Flow | -64.56M | -55.70M | -34.54M | -25.09M | -22.89M |
Error: Invalid format in Holders JSON file.
Article
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dec 2, 2024
Article
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer.
Oct 21, 2024
Article
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).
Oct 18, 2024
